Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

Core Insights - Rezolute, Inc. has appointed Sunil Karnawat as Chief Commercial Officer to lead the launch strategy and global market readiness for its therapy, ersodetug, which is currently in Phase 3 studies for treating hyperinsulinism [1][2] Company Overview - Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI) with its antibody therapy, ersodetug, which has shown meaningful benefits in clinical trials [4] Leadership Appointment - Sunil Karnawat brings over 25 years of experience in global commercialization of biopharmaceuticals and medical devices, having successfully launched products in various therapeutic areas, including ultra-rare diseases [2] - Karnawat's previous roles include Vice President at Cytokinetics and Ultragenyx, where he led the launch of four ultra-rare disease products [2] - His educational background includes an MBA from the Wharton School and a Ph.D. in Engineering [2] Inducement Grant - In connection with Karnawat's appointment, the Board of Directors approved an inducement stock option of 275,000 shares at an exercise price of $6.55 per share, with a vesting schedule tied to his continued employment [3]